5247152026-04-275247152026-04-272026-04-275247152026-04-27in-capmkt:FinancialYear1Member5247152026-04-27in-capmkt:FinancialYear2Member5247152026-04-27in-capmkt:FinancialYear3Member5247152026-04-272026-04-27in-capmkt:FinancialYear1Member5247152026-04-272026-04-27in-capmkt:FinancialYear2Member5247152026-04-272026-04-27in-capmkt:FinancialYear3Memberiso4217:INRxbrli:pure524715SUN PHARMACEUTICAL INDUSTRIES LIMITEDSUNPHARMANOTLISTEDINE044A01036NewAcquisition (including agreement to acquire)false2026-04-2705:12:002026-04-27Sun Pharmaceutical Holdings USA, Inc.Step Down SubsidiaryOrganon & Co.5416900000001620000000067620000000falsefalsetruePharmaceutical and HealthcareThe proposed acquisition of Organon & Co. is in line with the Company’s strategic objective of strengthening and diversifying its global pharmaceutical business. The transaction is expected to enhance the Company’s scale, geographic reach and product portfolio, particularly in women’s health, established branded medicines and biosimilars, and to support long term growth and value creation for shareholders.YesThe proposed acquisition is subject to customary closing conditions, including receipt of applicable regulatory approvals and statutory approval including, approvals by Organon stockholders and other approvals, if any, under applicable competition and antitrust laws (including expiration or termination of necessary waiting periods), and compliance with applicable regulatory and contractual requirements, as well as satisfaction of customary closing conditions.falseThe acquisition is expected to be completed in early 2027, subject to customary conditions, including regulatory approvals and Organon stockholder approval.Cash376490000000$ 14.00 per share in cash, or approximately $ 3.99 Billion in total equity value. The acquisition will be effected by acquiring all the outstanding shares of Organon in an all-cash transaction with an enterprise valuation of approximately $ 11.75 Billion.37649000000001Organon is a global pharmaceutical company incorporated in 2020 and headquartered in Jersey City, New Jersey, USA, and was spun off from Merck & Co. in June 2021. The company operates across three primary lines of business, namely women’s health, biosimilars, and established branded medicines.2024-20255416900000002023-20245357000000002022-2023517240000000United States of AmericaThe transaction is proposed to be implemented through a merger structure pursuant to which an overseas wholly owned subsidiary of the Company will merge with and into Organon, with Organon continuing as the surviving corporation. Upon successful completion of the transaction, Organon will be delisted from the New York Stock Exchange.